{"id":295324,"date":"2026-02-12T00:00:00","date_gmt":"2026-02-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneop0007-2023-biopharma-dry-and-wet-age-related-macular-degeneration-unmet-need-unmet-need-wet-age\/"},"modified":"2026-03-31T10:23:29","modified_gmt":"2026-03-31T10:23:29","slug":"unneop0007-2026-biopharma-dry-and-wet-age-related-macular-degeneration-unmet-need-unmet-need-wet-age-related-macular","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneop0007-2026-biopharma-dry-and-wet-age-related-macular-degeneration-unmet-need-unmet-need-wet-age-related-macular\/","title":{"rendered":"Dry and Wet Age-Related Macular Degeneration &#8211; Unmet Need &#8211; Unmet Need &#8211; Wet Age-Related Macular Degeneration (US\/EU)"},"content":{"rendered":"<p>Wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> (age-related macular degeneration) is a leading cause of vision loss among older adults, with significant implications on patient\u2019s independence and quality of life. The treatment landscape is dominated by intravitreal therapies such as Eylea, Eylea <abbr title=\"high-dose\">HD<\/abbr>, and Vabysmo, which have established strong patient share in both the United States and <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>. Despite these options, unmet needs persist, particularly around reducing treatment burden, sustained vision benefits, and addressing variability in patient response. The late-phase pipeline is active, with emerging long-term treatment options such as gene therapies (i.e., AbbVie \/ Regenxbio\u2019s sura-vec, Adverum \/ Eli Lilly\u2019s ixo-vec, and 4DMT \/ Otsuka\u2019s 4D-150) and resorbable intravitreal implant formulations of tyrosine kinase inhibitors (e.g., EyePoint\u2019s Duravyu, Ocular Therapeutix\u2019s Axpaxli) aiming to reshape market dynamics. As competition intensifies, understanding ophthalmologists\u2019 prescribing behaviors and the evolving expectations for convenience and efficacy will be critical for strategic positioning in this dynamic market.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How do wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> therapies perform on key clinical attributes?<\/li>\n<li>What are the prevailing areas of unmet need in wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> treatment?<\/li>\n<li>What trade-offs are surveyed ophthalmologists willing to make across key clinical attributes and price for a new therapy for wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr>?<\/li>\n<li>What factors will drive adoption of novel therapies in this competitive landscape?<\/li>\n<\/ul>\n<p><b>Geography: <\/b>United States, France, Germany, United Kingdom<\/p>\n<p><strong>Primary research:<\/strong> Survey of 60 U.S. and 31 European ophthalmologists<\/p>\n<p><strong>Key drugs covered:<\/strong>\u00a0Eylea, Eylea <abbr title=\"high-dose\">HD<\/abbr>, Vabysmo<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p><a>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/a><\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/li>\n<\/ul>\n<p><strong>Key feature:<\/strong> The Target Product Profile (<abbr title=\"Target Product Profile\">TPP<\/abbr>) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven <abbr title=\"Target Product Profile\">TPP<\/abbr>s across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n","protected":false},"template":"","class_list":["post-295324","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-age-related-macular-degeneration","biopharma-therapy-areas-ophthalmology","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295324\/revisions"}],"predecessor-version":[{"id":575203,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295324\/revisions\/575203"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}